Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
A Phase I Study of DS-3032B in Combination with Quizartinib in Subjects with FLT3-ITD Mutant Acute Myeloid Leukemia That are Relapsed/Refractory, or Newly Diagnosed and Unfit for Intensive Chemotherapy
A Phase III Randomized, Double-Blind Trial to Evaluate the Efficacy of Uproleselan Administered with Chemotherapy versus Chemotherapy Alone in Patients with Relapsed/Refractory Acute Myeloid Leukemia
A Phase I/II Study of Oral LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma CLL/SLL or Non-Hodgkin Lymphoma NHL
Study Type: Treatment
Phase: I/II
NCTID: NCT03740529
Principal Investigator:
Marc Hoffmann
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
Study Type: Treatment
Phase: III
NCTID: NCT03959085
Principal Investigator:
Keith August
An Open-Label, Phase I, Multi-Center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome or B-Cell Non-Hodgkin Lymphoma Patients the Recommended Dose of CYAD-02 After A Non-Myeloablative Preconditioning Chemotherapy Followed By A Potential CYAD-02 Consolidation Cycle for Non-Progressive Patients CYCLE-1 ? CYAD-02 NKG2D CAR-T Clinical dEvelopment
A Phase 1/2, Multi-Center, Open-Label, Single-Arm, Dose-Escalation, Clinical Study To Evaluate The Safety, Tolerability, Pharmacokinetics PK And Anti-Tumor Activity of FN-1501 Monotherapy In Patients with Advanced Solid Tumors or Relapsed/Refractory Acute Myeloid Leukemia AML
A Phase I Study to Evaluate the Safety and Pharmacokinetics of CB-5339 in Participants with Relapsed/Refractory Acute Myeloid Leukemia or Intermediate-High Risk Myelodysplastic Syndrome
A Phase III, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome?Positive Acute Lymphoblastic Leukemia Ph+ ALL
Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Study Type: Treatment
Phase: I
NCTID: NCT02303821
Principal Investigator:
Kevin Ginn
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Study Type: Treatment
Phase: III
NCTID: NCT03007147
Principal Investigator:
Keith August